In the present study, the respective role of membrane and nuclear ERα signaling of E2 on ER-negative tumor growth and angiogenesis was evaluated in parallel with the effects of tamoxifen, which was the first clinically approved ER-targeted agent. The gene discussed is ERAL1; the disease is neoplasm.